EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance

Daniele Focosi iD

Viruses · 2023

DOI: 10.3390/v15051048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Daniele Focosi. Beteiligte Einrichtung: North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug appropriateness is a pillar of modern evidence-based medicine, but the turnaround times of genomic sequencing are not compatible with the urgent need to deliver treatments against microorganisms. Massive worldwide genomic surveillance has created an unprecedented landscape for exploiting viral sequencing for therapeutic purposes. When it comes to therapeutic antiviral antibodies, using IC50 against specific polymorphisms of the target antigen can be calculated in vitro, and a list of mutations leading to drug resistance (immune escape) can be compiled. The author encountered this type of knowledge (available from the Stanford University Coronavirus Antiviral Resistance Database,) in a publicly accessible repository of SARS-CoV-2 sequences. The author used a custom function of the CoV-Spectrum.org web portal to deliver up-to-date, regional prevalence estimates of baseline efficacy for each authorized anti-spike mAb across all co-circulating SARS-CoV-2 sublineages at a given time point. This publicly accessible tool can inform therapeutic choices that would otherwise be blind.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2GenomicsAntibodies, MonoclonalAntibodies, ViralAntiviral AgentsSpike Glycoprotein, CoronavirusAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19CoV-SpectrumEvusheldGISAIDSARS-CoV-2anti-spike monoclonal antibodies

Substanzen

Antibodies, MonoclonalAntibodies, ViralAntiviral AgentsSpike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

ORCID-Profile: Daniele Focosi

Zitieren

APA

Focosi, D. (2023). A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance. Viruses. https://doi.org/10.3390/v15051048

Vancouver

Focosi D. A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance. Viruses. 2023. doi:10.3390/v15051048

BibTeX
@article{Focosi2023,
  author = {Focosi, Daniele},
  title = {A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15051048}
}
Kostenlos starten →